Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 736856, 16 pages
http://dx.doi.org/10.1155/2013/736856
Review Article

Beneficial Effect of 7-O-Galloyl-D-sedoheptulose, a Polyphenol Isolated from Corni Fructus, against Diabetes-Induced Alterations in Kidney and Adipose Tissue of Type 2 Diabetic db/db Mice

1College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea
2Department of Food Science & Nutrition, Pusan National University, Busan 609-735, Republic of Korea
3Department of Oriental Medicine Resources, Sunchon National University, Jeonnam 540-742, Republic of Korea
4Graduate School of Science and Engineering for Research, University of Toyama, Toyama 930-8555, Japan
5Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan 609-735, Republic of Korea

Received 2 August 2013; Accepted 7 September 2013

Academic Editor: Yong-Ouk You

Copyright © 2013 Chan Hum Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Stumvoll, B. J. Goldstein, and T. W. Van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” The Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Poitout and R. P. Robertson, “Glucolipotoxicity: fuel excess and β-cell dysfunction,” Endocrine Reviews, vol. 29, no. 3, pp. 351–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Brownlee, A. Cerami, and H. Vlassara, “Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications,” New England Journal of Medicine, vol. 318, no. 20, pp. 1315–1321, 1988. View at Google Scholar · View at Scopus
  4. R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: a review,” Diabetologia, vol. 44, no. 2, pp. 129–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Inoguchi, R. Battan, E. Handler, J. R. Sportsman, W. Heath, and G. L. King, “Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 22, pp. 11059–11063, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Koya and G. L. King, “Protein kinase C activation and the development of diabetic complications,” Diabetes, vol. 47, no. 6, pp. 859–866, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Yabe-Nishimura, “Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications,” Pharmacological Reviews, vol. 50, no. 1, pp. 21–33, 1998. View at Google Scholar · View at Scopus
  8. J. V. Hunt, R. T. Dean, and S. P. Wolff, “Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing,” Biochemical Journal, vol. 256, no. 1, pp. 205–212, 1988. View at Google Scholar · View at Scopus
  9. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Bonnefont-Rousselot, J. P. Bastard, M. C. Jaudon, and J. Delattre, “Consequences of the diabetic status on the oxidant/antioxidant balance,” Diabetes and Metabolism, vol. 26, no. 3, pp. 163–176, 2000. View at Google Scholar · View at Scopus
  11. V. Jakus, “The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease,” Bratislavské Lekárske Listy, vol. 101, no. 10, pp. 541–551, 2000. View at Google Scholar · View at Scopus
  12. I. C. West, “Radicals and oxidative stress in diabetes,” Diabetic Medicine, vol. 17, no. 3, pp. 171–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Miyata, “Alterations of non-enzymatic biochemistry in uremia, diabetes, and atherosclerosis (“carbonyl stress”),” Bulletin et Mémoires de l'Académie Royale de Médecine de Belgique, vol. 157, no. 3-4, pp. 189–196, 2002. View at Google Scholar · View at Scopus
  14. A. F. Ceylan-Isik, R. M. Fliethman, L. E. Wold, and J. Ren, “Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus,” Current Diabetes Reviews, vol. 4, no. 4, pp. 320–328, 2008. View at Google Scholar · View at Scopus
  15. W. L. Li, H. C. Zheng, J. Bukuru, and N. De Kimpe, “Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus,” Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Chang, L. C. Chiang, F. F. Hsu, and C. C. Lin, “Chemoprevention against hepatocellular carcinoma of Cornus officinalis in vitro,” American Journal of Chinese Medicine, vol. 32, no. 5, pp. 717–725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. S. Liou, I. M. Liu, S. F. Hsu, and J. T. Cheng, “Corni Fructus as the major herb of Die-Huang-Wan for lowering plasma glucose in Wistar rats,” Journal of Pharmacy and Pharmacology, vol. 56, no. 11, pp. 1443–1447, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. K. Vareed, M. K. Reddy, R. E. Schutzki, and M. G. Nair, “Anthocyanins in Cornus alternifolia, Cornus controversa, Cornus kousa and Cornus florida fruits with health benefits,” Life Sciences, vol. 78, no. 7, pp. 777–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Yamabe, K. S. Kang, E. Goto, T. Tanaka, and T. Yokozawa, “Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats,” Biological & Pharmaceutical Bulletin, vol. 30, no. 3, pp. 520–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. H. Park, E. J. Cho, and T. Yokozawa, “Protection against hypercholesterolemia by Corni Fructus extract and its related protective mechanism,” Journal of Medicinal Food, vol. 12, no. 5, pp. 973–981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. H. Park, N. Yamabe, J. S. Noh, K. S. Kang, T. Tanaka, and T. Yokozawa, “The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice,” Biological & Pharmaceutical Bulletin, vol. 32, no. 10, pp. 1734–1740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C. H. Park, J. S. Noh, T. Tanaka, and T. Yokozawa, “Effects of morroniside isolated from Corni Fructus on renal lipids and inflammation in type 2 diabetic mice,” Journal of Pharmacy and Pharmacology, vol. 62, no. 3, pp. 374–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. H. Park, J. S. Noh, N. Yamabe, K. S. Kang, T. Tanaka, and T. Yokozawa, “Beneficial effect of 7-O-galloyl-d-sedoheptulose on oxidative stress and hepatic and renal changes in type 2 diabetic db/db mice,” European Journal of Pharmacology, vol. 640, no. 1–3, pp. 233–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Yamabe, J. S. Noh, C. H. Park et al., “Evaluation of loganin, iridoid glycoside from Corni Fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice,” European Journal of Pharmacology, vol. 648, no. 1–3, pp. 179–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. H. Park, J. S. Noh, J. H. Kim et al., “Evaluation of morroniside, iridoid glycoside from Corni Fructus, on diabetes-induced alterations such as oxidative stress, inflammation, and apoptosis in the liver of type 2 diabetic db/db mice,” Biological & Pharmaceutical Bulletin, vol. 34, no. 10, pp. 1559–1565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. C. H. Park, T. Tanaka, J. H. Kim et al., “Hepato-protective effects of loganin, iridoid glycoside from Corni Fructus, against hyperglycemia-activated signaling pathway in liver of type 2 diabetic db/db mice,” Toxicology, vol. 290, no. 1, pp. 14–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. S. Noh, C. H. Park, T. Tanaka, and T. Yokozawa, “7-O-Galloyl-d-sedoheptulose attenuates oxidative stress-induced diabetic injury via decreasing expression of nuclear factor-kB- and apoptosis-related protein in the liver,” Biological & Pharmaceutical Bulletin, vol. 35, no. 6, pp. 950–956, 2012. View at Google Scholar
  28. C. H. Park, J. S. Noh, T. Tanaka, and T. Yokozawa, “7-O-Galloyl-d-sedoheptulose ameliorates renal damage triggered by reactive oxygen species-sensitive pathway of inflammation and apoptosis,” Journal of Pharmacy and Pharmacology, vol. 64, no. 12, pp. 1730–1740, 2012. View at Google Scholar
  29. C. H. Park, T. Tanaka, and T. Yokozawa, “Anti-diabetic action of 7-O-galloyl-d-sedoheptulose, a polyphenol from Corni Fructus, through ameliorating inflammation and inflammation-related oxidative stress in the pancreas of type 2 diabetics,” Biological & Pharmaceutical Bulletin, vol. 36, no. 5, pp. 723–732, 2013. View at Google Scholar
  30. C. H. Park, T. Tanaka, and T. Yokozawa, “Evaluation of 7-O-galloyl-d-sedoheptulose, isolated from Corni Fructus, in the adipose tissue of type 2 diabetic db/db mice,” Fitoterapia, vol. 89, pp. 131–142, 2013. View at Google Scholar
  31. Y. W. Zhang, Y. W. Chen, and S. P. Zhao, “A sedoheptulose gallate from the fruits of Cornus officinalis,” Acta Pharmaceutica Sinica, vol. 34, no. 2, pp. 153–155, 1999. View at Google Scholar · View at Scopus
  32. K. Sharma, P. McCue, and S. R. Dunn, “Diabetic kidney disease in the db/db mouse,” American Journal of Physiology: Renal Physiology, vol. 284, no. 6, pp. F1138–F1144, 2003. View at Google Scholar · View at Scopus
  33. H. B. Lee, M. R. Yu, Y. Yang, Z. Jiang, and H. Ha, “Reactive oxygen species-regulated signaling pathways in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 3, supplement, pp. S241–S245, 2003. View at Google Scholar · View at Scopus
  34. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Geiszt, J. B. Kopp, P. Várnai, and T. L. Leto, “Identification of renox, an NAD(P)H oxidase in kidney,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 8010–8014, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. K. A. Nath and S. M. Norby, “Reactive oxygen species and acute renal failure,” American Journal of Medicine, vol. 109, no. 8, pp. 665–678, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Shiose, J. Kuroda, K. Tsuruya et al., “A novel superoxide-producing NAD(P)H oxidase in kidney,” Journal of Biological Chemistry, vol. 276, no. 2, pp. 1417–1423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000. View at Google Scholar · View at Scopus
  39. G. Zalba, G. S. José, M. U. Moreno et al., “Oxidative stress in arterial hypertension: role of NAD(P)H oxidase,” Hypertension, vol. 38, no. 6, pp. 1395–1399, 2001. View at Google Scholar · View at Scopus
  40. P. S. Gill and C. S. Wilcox, “NADPH oxidases in the kidney,” Antioxidants & Redox Signaling, vol. 8, no. 9-10, pp. 1597–1607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. B. M. Babior, J. D. Lambeth, and W. Nauseef, “The neutrophil NADPH oxidase,” Archives of Biochemistry and Biophysics, vol. 397, no. 2, pp. 342–344, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Etoh, T. Inoguchi, M. Kakimoto et al., “Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment,” Diabetologia, vol. 46, no. 10, pp. 1428–1437, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Gorin, K. Block, J. Hernandez et al., “Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39616–39626, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Sedeek, G. Callera, A. Montezano et al., “Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy,” American Journal of Physiology: Renal Physiology, vol. 299, no. 6, pp. F1348–F1358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Kumar, S. Robertson, and K. D. Burns, “Evidence of apoptosis in human diabetic kidney,” Molecular and Cellular Biochemistry, vol. 259, no. 1-2, pp. 67–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Susztak, A. C. Raff, M. Schiffer, and E. P. Böttinger, “Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy,” Diabetes, vol. 55, no. 1, pp. 225–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. P. A. Baeuerle and T. Henkel, “Function and activation of NF-κB in the immune system,” Annual Review of Immunology, vol. 12, pp. 141–179, 1994. View at Google Scholar · View at Scopus
  48. C. Viedt, G. M. Hänsch, R. P. Brandes, W. Kübler, and J. Kreuzer, “The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κ B and AP-1,” The FASEB Journal, vol. 14, no. 15, pp. 2370–2372, 2000. View at Google Scholar · View at Scopus
  49. Y. J. Surh, K. S. Chun, H. H. Cha et al., “Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation,” Mutation Research, vol. 480-481, pp. 243–268, 2001. View at Google Scholar · View at Scopus
  50. M. Kömhoff, H. J. Grone, T. Klein, H. W. Seyberth, and R. M. Nüsing, “Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function,” American Journal of Physiology: Renal Physiology, vol. 272, no. 4, pp. F460–F468, 1997. View at Google Scholar · View at Scopus
  51. P. A. Adegboyega and O. Ololade, “Immunohistochemical expression of cyclooxygenase-2 in normal kidneys,” Applied Immunohistochemistry & Molecular Morphology, vol. 12, no. 1, pp. 71–74, 2004. View at Google Scholar · View at Scopus
  52. E. B. Rangel, L. A. Moura, M. Franco, and A. Pacheco-Silva, “Expression of cyclooxygenases during renal allograft rejection,” Transplantation Proceedings, vol. 36, no. 4, pp. 838–839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. É. B. Rangel, L. A. Moura, M. F. Franco, and Á. Pacheco-Silva, “Up-regulation of cyclooxygenase-2 during acute human renal allograft rejection,” Clinical Transplantation, vol. 19, no. 4, pp. 543–550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Cheng, X. Fan, G. W. Moeckel, and R. C. Harris, “Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1240–1251, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Tian, J. Liu, P. B. Bitterman, and R. J. Bache, “Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 283, no. 5, pp. H1958–H1967, 2002. View at Google Scholar · View at Scopus
  56. J. A. Corbett, G. Kwon, T. P. Misko, C. P. Rodi, and M. L. McDaniel, “Tyrosine kinase involvement in IL-1β-induced expression of iNOS by β-cells purified from islets of Langerhans,” American Journal of Physiology: Cell Physiology, vol. 267, no. 1, pp. C48–C54, 1994. View at Google Scholar · View at Scopus
  57. R. Medeiros, R. D. Prediger, G. F. Passos et al., “Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein,” Journal of Neuroscience, vol. 27, no. 20, pp. 5394–5404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Frühbeck, J. Gómez-Ambrosi, F. J. Muruzábal, and M. A. Burrell, “The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation,” American Journal of Physiology: Endocrinology and Metabolism, vol. 280, no. 6, pp. E827–E847, 2001. View at Google Scholar · View at Scopus
  59. P. Srikanthan and W. Hsueh, “Preventing heart failure in patients with diabetes,” Medical Clinics of North America, vol. 88, no. 5, pp. 1237–1256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. M. Younossi, T. Gramlich, C. A. Matteoni, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease in patients with type 2 diabetes,” Clinical Gastroenterology and Hepatology, vol. 2, no. 3, pp. 262–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. K. J. Chang-Chen, R. Mullur, and E. Bernal-Mizrachi, “β-Cell failure as a complication of diabetes,” Reviews in Endocrine & Metabolic Disorders, vol. 9, no. 4, pp. 329–343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. S. Kanwar, J. Wada, L. Sun et al., “Diabetic nephropathy: mechanisms of renal disease progression,” Experimental Biology and Medicine, vol. 233, no. 1, pp. 4–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. C. Maritim, R. A. Sanders, and J. B. Watkins III, “Diabetes, oxidative stress, and antioxidants: a review,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 24–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. A. P. Rolo and C. M. Palmeira, “Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress,” Toxicology and Applied Pharmacology, vol. 212, no. 2, pp. 167–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Nishikawa and E. Araki, “Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications,” Antioxidants & Redox Signaling, vol. 9, no. 3, pp. 343–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Gao and G. E. Mann, “Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signaling,” Cardiovascular Research, vol. 82, no. 1, pp. 9–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. A. Lee, Y. J. Kim, E. J. Cho, and T. Yokozawa, “Ameliorative effects of proanthocyanidin on oxidative stress and inflammation in streptozotocin-induced diabetic rats,” Journal of Agricultural and Food Chemistry, vol. 55, no. 23, pp. 9395–9400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. C. de Luca and J. M. Olefsky, “Inflammation and insulin resistance,” FEBS Letters, vol. 582, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. C. B. Guest, M. J. Park, D. R. Johnson, and G. G. Freund, “The implication of proinflammatory cytokines in type 2 diabetes,” Frontiers in Bioscience, vol. 13, no. 13, pp. 5187–5194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. F. Ndisang, “Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity,” Mediators of Inflammation, vol. 2010, Article ID 359732, 18 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. N. B. Kumar, A. Kazi, T. Smith et al., “Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment,” Current Treatment Options in Oncology, vol. 11, no. 3-4, pp. 107–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Shan, J. Fu, Z. Zhao et al., “Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-κB and JNK/AP-1 activation,” International Immunopharmacology, vol. 9, no. 9, pp. 1042–1048, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Kaneto, T. A. Matsuoka, N. Katakami et al., “Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes,” Current Molecular Medicine, vol. 7, no. 7, pp. 674–686, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology—LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Fonseca, “Effect of thiazolidinediones on body weight in patients with diabetes mellitus,” American Journal of Medicine, vol. 115, no. 8, supplement, pp. 42S–48S, 2003. View at Publisher · View at Google Scholar · View at Scopus